Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-25T09:08:36.539Z Has data issue: false hasContentIssue false
  • English
  • Français

The National Institutes of Health Attention-Deficit/Hyperactivity Disorder Consensus Statement: Implications for Practitioners and Scientists

Published online by Cambridge University Press:  07 November 2014

Peter S. Jensen
Get access Rights & Permissions [Opens in a new window]

Abstract

Although the concept of pharmacotherapyfor attention-deficit/hyperactivity disorder (ADHD) was first introduced more than 60 years ago, treatment of this disorder remains more controversial than ever. It is hoped, however, that the recent Consensus Development Conference (CDC) Statement on the diagnosis and treatment of ADHD will not only help answer some of the questions surrounding management of this disorder, but also lend needed scientific weight to debate in this area. While more research in ADHD is needed, the CDC partic ipants pointed to a solid body of evidence showing that careful medication management can result in noticeable improvement in several measures, with little risk of adverse events.

Type
Feature Article
Information
CNS Spectrums , Volume 5 , Issue 6: Toward a Fresh Understanding of ADHD , June 2000 , pp. 29 - 33
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:182–93.CrossRefGoogle Scholar
2.Bradley, C. The behavior of children receiving benzadrine. Am J Psychiatry. 1937;94:577–585.CrossRefGoogle Scholar
3.Pelham, WE, Wheeler, T, Chronis, A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol. 1998;27:190–205.CrossRefGoogle ScholarPubMed
4.Spencer, T, Biederman, J, Wilens, T, et al.Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409–432.CrossRefGoogle ScholarPubMed
5.McMaster University Evidence-based Practice Center. The Treatment of Attention-Deficit/Hyperactivity Disorder: An Evidence Report. Ontario, Canada: Agency for Health Care Policy and Research; 1999. Contract No. 290-97-0017.Google Scholar
6.MTA Cooperative Group. 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–1086.CrossRefGoogle Scholar
7.MTA Cooperative Group. Moderator and mediator challenges to the MTA study: Effects of comorbid anxiety disorder, family poverty, session attendance, and community medication on treatment outcome. Arch Gen Psychiatry. 1999;56:1088–1096.Google Scholar
8.Hinshaw, SP, Henker, B, Whalen, CK, et al.Aggressive, prosocial, and nonsocial behavior in hyperactive boys: dose effects of methylphenidate in naturalistic settings. J Cons Clin Psychol. 1989;57:636–643.CrossRefGoogle ScholarPubMed
9.Chilcoat, HD, Breslau, N. Pathways from ADHD to early drug use. J Am Acad Child Adolesc Psychiatry. 1999;38(11):1347–1354.CrossRefGoogle ScholarPubMed
10.Disney, ER, Elkins, IJ, McGue, M, et al.Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry. 1999;156(10):1515–1521.CrossRefGoogle ScholarPubMed